Evaluation of clinical efficacy and prognosis of luspatercept in the treatment of myelodysplastic syndrome based on red blood cell distribution width and Cyr61

LIU Gengrong, LI Wenbin, LI Guihu

PDF(1580 KB)
Tumor website：www.tumorsci.org E-mail Alert
PDF(1580 KB)
Tumor ›› 2025, Vol. 45 ›› Issue (03) : 276-286. DOI: 10.3781/j.issn.1000-7431.2025.2408-0476
Original Research

Evaluation of clinical efficacy and prognosis of luspatercept in the treatment of myelodysplastic syndrome based on red blood cell distribution width and Cyr61

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2025, 45(03): 276-286 https://doi.org/10.3781/j.issn.1000-7431.2025.2408-0476

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(1580 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © Tumor, All Rights Reserved.
E-mail: tumor@tumorsci.org
Powered by Beijing Magtech Co., Ltd.

/

〈 〉